FDA Approves Clinolipid to Address Drug Shortage
The FDA has approved Clinolipid (lipid injectable emulsion; Baxter) for parenteral nutrition in adult patients who are unable to eat or drink.
Clinolipid is a lipid emulsion that contains a mixture of refined olive oil and refined soybean oil. The fatty acids contained in Clinolipid serve as an important source of energy in patients receiving parenteral nutrition.
In May 2013, the FDA addressed a shortage on injectable nutrition drugs, and Clinolipid was granted priority review to help alleviate this drug shortage.
The safety and efficacy of Clinolipid were evaluated in studies comparing Clinolipid with a soybean oil-based lipid emulsion. Clinolipid was shown to be an effective source of energy in adult patients. Clinolipid is not indicated for use in preterm infants or pediatric patients.
For more information call (800) 262-3784 or visit Baxter.com.